Prof., senior consultant
Claus Bistrup
Dept. of Nephrology
Projekt styring | ||
Projekt status | Open | |
Data indsamlingsdatoer | ||
Start | 01.12.2023 | |
Slut | 01.02.2025 | |
Varicella zoster virus (VZV) is a vaccine-preventable disease that causes varicella during primary infection and herpes zoster when reactivated later in life. Kidney transplant recipients have high risk of herpes zoster. Until last year, the only available VZV/herpes zoster vaccines in Europe were live vaccines, and live vaccines are contraindicated in immunosuppressed individuals. We want to the the non-live herpes zoster vaccine in immunosuppressed organ transplant recipeints.
1) To determine the antibody vaccine response rate of herpes zoster vaccination (Shingrix®) in kidney transplant recipients that are vaccinated at different time points before and after transplantation and risk factors for non-response. 2) To determine the T cell immunogenicity of herpes zoster vaccination (Shingrix®) in kidney transplant recipients that are vaccinated at different time points before and after transplantation. 3) To determine the antibody persistence after herpes zoster vaccination (Shingrix®) in kidney transplant recipients that are vaccinated at different time points before and after transplantation.
Kidney transplant recipients and patients on the waiting list for kidney transplantation
Blood samples
Dept. of infectious diseases & Dept. of nephrology Copenhagen University Hospital, Dept. of nephrology Aarhus University hospital, Dept. of health technology, Technical University of Denmark